{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:59:32Z","timestamp":1791266372718,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,4,26]],"date-time":"2007-04-26T00:00:00Z","timestamp":1177545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1007\/s11904-007-0008-7","type":"journal-article","created":{"date-parts":[[2007,4,25]],"date-time":"2007-04-25T15:21:04Z","timestamp":1177514464000},"page":"53-59","source":"Crossref","is-referenced-by-count":5,"title":["Should antiretroviral therapy be started earlier?"],"prefix":"10.1007","volume":"4","author":[{"given":"Joel E.","family":"Gallant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,4,26]]},"reference":[{"key":"8_CR1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","volume":"337","author":"R.M. Gulick","year":"1997","unstructured":"Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734\u2013739.","journal-title":"N Engl J Med"},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/387188a0","volume":"387","author":"A.S. Perlson","year":"1997","unstructured":"Perlson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188\u2013191.","journal-title":"Nature"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D. Finzi","year":"1997","unstructured":"Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295\u20131300.","journal-title":"Science"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1126\/science.278.5341.1291","volume":"278","author":"J.K. Wong","year":"1997","unstructured":"Wong JK, Hezarch M, Gunthard HF, et al.: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291\u20131295.","journal-title":"Science"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.95.15.8869","volume":"95","author":"T.-W. Chun","year":"1998","unstructured":"Chun T-W, Engel D, Berrey MM, et al.: Early establishment of a pool of latently infected, resting CD4+T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998, 95:8869\u20138873.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8_CR6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","volume":"360","author":"M. Egger","year":"2002","unstructured":"Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119\u2013129.","journal-title":"Lancet"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/378301","volume":"37","author":"A.K. Sethi","year":"2003","unstructured":"Sethi AK, Celentano DD, Gange SJ, et al.: Association between adherence with antiretroviral therapy and HIV drug resistance. Clin Infect Dis 2003, 37:1112\u20131118.","journal-title":"Clin Infect Dis"},{"key":"8_CR8","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A. Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51\u201358.","journal-title":"AIDS"},{"key":"8_CR9","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(02)11672-2","volume":"360","author":"S.D. Holmberg","year":"2002","unstructured":"Holmberg SD, Moorman AC, Williamson JC, et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002, 360:1747\u20131748.","journal-title":"Lancet"},{"key":"8_CR10","unstructured":"Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. http:\/\/aidsinfo.nih.gov . Accessed January 14, 2007."},{"key":"8_CR11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","volume":"206","author":"S.M. Hammer","year":"2006","unstructured":"Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel. JAMA 2006, 206:827\u2013843.","journal-title":"JAMA"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","volume":"354","author":"J.E. Gallant","year":"2006","unstructured":"Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251\u2013260.","journal-title":"N Engl J Med"},{"key":"8_CR13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"J.E. Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-na\u00efve patients: a randomized trial. JAMA 2004, 292:191\u2013201.","journal-title":"JAMA"},{"key":"8_CR14","unstructured":"Friis-Moller N, Reiss P, El-Sadr W, et al.: Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D study [abstract 144]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5\u20138, 2006."},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-131-2-199907200-00002","volume":"131","author":"G.M. Lucas","year":"1999","unstructured":"Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81\u201387.","journal-title":"Ann Intern Med"},{"key":"8_CR16","unstructured":"Lichtenstein KA, Armon C, Buchacz K, et al.: Early, uninterrupted ART is associated with improved outcome and fewer toxicities in the HIV Outpatient Study (HOPS) [abstract 769]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5\u20138, 2006."},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","volume":"133","author":"D.L. Paterson","year":"2000","unstructured":"Paterson DL, Swindells S, Mohr J, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21\u201330.","journal-title":"Ann Intern Med"},{"key":"8_CR18","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","volume":"346","author":"S. Walmsley","year":"2002","unstructured":"Walmsley S, Bernstein B, King M, et al.: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002, 346:2039\u20132046.","journal-title":"N Engl J Med"},{"key":"8_CR19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/507526","volume":"43","author":"D. Bangsberg","year":"2006","unstructured":"Bangsberg D: Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006, 43:939\u2013941.","journal-title":"Clin Infect Dis"},{"key":"8_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/380509","volume":"189","author":"D.J. Kempf","year":"2004","unstructured":"Kempf DJ, King MS, Bernstein B, et al.: Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004, 189:51\u201360.","journal-title":"J Infect Dis"},{"key":"8_CR21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.aids.0000131332.30548.92","volume":"18","author":"J.C. Gathe Jr","year":"2004","unstructured":"Gathe JC Jr, Ive P, Wood R, et al.: SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir\/ritonavir versus twice-daily nelfinavir in na\u00efve HIV-1-infected patients. AIDS 2004, 18:1529\u20131537.","journal-title":"AIDS"},{"key":"8_CR22","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/01.aids.0000247578.08449.ff","volume":"20","author":"J.A. Bartlett","year":"2006","unstructured":"Bartlett JA, Fath MJ, Demasi R, et al.: An updated systematic overview of triple combination therapy in antiretroviralnaive HIV-infected adults. AIDS 2006, 20:2051\u20132064.","journal-title":"AIDS"},{"key":"8_CR23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/archinte.166.5.521","volume":"166","author":"F.C. Lampe","year":"2006","unstructured":"Lampe FC, Gatell JM, Staszewski S, et al.: Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006, 166:521\u2013528.","journal-title":"Arch Intern Med"},{"key":"8_CR24","first-page":"195","volume":"39","author":"R.D. Moore","year":"2005","unstructured":"Moore RD, Keruly JC, Gebo KA, Lucas GM: An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquire Immune Defic Syndr 2005, 39:195\u2013198.","journal-title":"J Acquire Immune Defic Syndr"},{"key":"8_CR25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/00002030-200207050-00009","volume":"16","author":"M. Opravil","year":"2002","unstructured":"Opravil M, Ledergerber B, Furrer H, et al.: Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 \u00d7 10(6)\/1. AIDS 2002, 16:1371\u20131381.","journal-title":"AIDS"},{"key":"8_CR26","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1086\/379741","volume":"188","author":"T.R. Sterling","year":"2003","unstructured":"Sterling TR, Chaisson RE, Keruly J, Moore RD: Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003, 188:1659\u20131665.","journal-title":"J Infect Dis"},{"key":"8_CR27","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1086\/422848","volume":"190","author":"C. Wang","year":"2004","unstructured":"Wang C, Vlahov D, Galai N, et al.: Mortality in HIV-seropositive versus-seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004, 190:1046\u20131054.","journal-title":"J Infect Dis"},{"key":"8_CR28","unstructured":"Sterne J, May M, Costagliola D, et al.: Estimating the optimum CD4 threshold for starting HAART in ART-na\u00efve HIV-infected individuals [abstract 525]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5\u20138, 2006."},{"key":"8_CR29","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/0003-4819-124-7-199604010-00003","volume":"124","author":"R.C. Chaisson","year":"1996","unstructured":"Chaisson RC, Moore RD: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996, 124:633\u2013642.","journal-title":"Ann Intern Med"},{"key":"8_CR30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","volume":"126","author":"J.W. Mellors","year":"1997","unstructured":"Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946\u2013954.","journal-title":"Ann Intern Med"},{"key":"8_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200401020-00006","volume":"18","author":"A. Phillips","year":"2004","unstructured":"Phillips A, CASCADE Collaboration: Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004, 18:51\u201358.","journal-title":"AIDS"},{"key":"8_CR32","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","volume":"355","author":"Strategies for Management of Antiretroviral Therapy","year":"2006","unstructured":"Strategies for Management of Antiretroviral Therapy (SMART) Study Group: CD4-guided antiretroviral treatment interruption: primary results of the SMART study. N Engl J Med 2006, 355:2283\u20132296.","journal-title":"N Engl J Med"},{"key":"8_CR33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-138-8-200304150-00007","volume":"138","author":"F.J. Palella Jr","year":"2003","unstructured":"Palella FJ Jr, Knoll MD, Chmiel JS, et al.: Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003, 138:620\u2013626.","journal-title":"Ann Intern Med"},{"key":"8_CR34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1097\/00002030-200009080-00007","volume":"14","author":"M. Plana","year":"2000","unstructured":"Plana M, Garcia F, Gallart T, et al.: Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. AIDS 2000, 14:1921\u20131933.","journal-title":"AIDS"},{"key":"8_CR35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11908-005-0050-9","volume":"7","author":"V. Appay","year":"2005","unstructured":"Appay V, Boutboul F, Autran B: The HIV infection and immune activation: \u201cto fight and burn\u201d. Curr Infect Dis Rep 2005, 7:473\u2013479.","journal-title":"Curr Infect Dis Rep"},{"key":"8_CR36","unstructured":"Gras L, Van Sighem A, Fraser C, et al.: Predictors for changes in CD4 cell count 7 years after starting HAART [abstract 530]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5\u20138, 2006."},{"key":"8_CR37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1086\/510746","volume":"44","author":"R.D. Moore","year":"2007","unstructured":"Moore RD, Keruly JC: CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007, 44:441\u2013446.","journal-title":"Clin Infect Dis"},{"key":"8_CR38","unstructured":"King M, Da Silva BA, McMillan F, et al.: When does the CD4 cell count plateau? Evidence from subjects treated with a lopinavir\/ritonavir-based regimen for up to 7 years [abstract H-1401]. Paper presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 27\u201330, 2006."},{"key":"8_CR39","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","volume":"342","author":"T.C. Quinn","year":"2000","unstructured":"Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921\u2013929.","journal-title":"N Engl J Med"},{"key":"8_CR40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002030-200401020-00010","volume":"18","author":"T.C. Porco","year":"2004","unstructured":"Porco TC, Martin JN, Page-Shafer KA, et al.: Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004, 18:81\u201388.","journal-title":"AIDS"},{"key":"8_CR41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00126334-200203010-00008","volume":"29","author":"S. Tovanabutra","year":"2002","unstructured":"Tovanabutra S, Robinson V, Wongtrakul J, et al.: Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002, 29:275\u2013283.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8_CR42","unstructured":"Gulick R, Su Z, Flexner C, et al.: ACTG 5211: phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects [abstract THLB0217]. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13\u201318, 2006."},{"key":"8_CR43","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-118-9-199305010-00004","volume":"118","author":"M. Koot","year":"1993","unstructured":"Koot M, Keet IP, Vos AH, et al.: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993, 118:681\u2013688.","journal-title":"Ann Intern Med"},{"key":"8_CR44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/428096","volume":"191","author":"G.J. Moyle","year":"2005","unstructured":"Moyle GJ, Wildfire A, Mandalia S, et al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005, 191:866\u2013872.","journal-title":"J Infect Dis"},{"key":"8_CR45","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.2105\/AJPH.91.9.1464","volume":"91","author":"J.G. Kahn","year":"2001","unstructured":"Kahn JG, Haile B, Kates J, Chang S: Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid. Am J Public Health 2001, 91:1464\u20131473.","journal-title":"Am J Public Health"},{"key":"8_CR46","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1086\/500453","volume":"42","author":"R.Y. Chen","year":"2006","unstructured":"Chen RY, Accortt NA, Westfall AO, et al.: Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis 2006, 42:1003\u20131010.","journal-title":"Clin Infect Dis"},{"key":"8_CR47","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1001\/archinte.162.21.2478","volume":"162","author":"B.R. Schackman","year":"2002","unstructured":"Schackman BR, Freedberg KA, Weinstein MC, et al.: Cost-effective implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002, 162:2478\u20132486.","journal-title":"Arch Intern Med"},{"key":"8_CR48","first-page":"562","volume":"39","author":"J. Mauskopf","year":"2005","unstructured":"Mauskopf J, Kitahata M, Kauf T, et al.: HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr 2005, 39:562\u2013569.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"8_CR49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1086\/317644","volume":"183","author":"M. Puoti","year":"2001","unstructured":"Puoti M, Bonacini M, Spinetti A, et al.: Liver fibrosis is related to CD4 depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001, 183:134\u2013137.","journal-title":"J Infect Dis"},{"key":"8_CR50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"C.S. Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562\u2013569.","journal-title":"Clin Infect Dis"},{"key":"8_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","volume":"26","author":"B. Soto","year":"1997","unstructured":"Soto B, Sanchez-Quijano A, Rodrigo L, et al.: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997, 26:1\u20135.","journal-title":"J Hepatol"},{"key":"8_CR52","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0b013e32801086da","volume":"20","author":"S.H. Mehta","year":"2006","unstructured":"Mehta SH, Lucas GM, Mirel LB, et al.: Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006, 20:2361\u20132369.","journal-title":"AIDS"},{"key":"8_CR53","doi-asserted-by":"crossref","unstructured":"Shafran SD: Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV\/hepatic C virus-coinfected patients. J Acquir Immune Defic Syndr 2007, In press.","DOI":"10.1097\/QAI.0b013e31803151c7"},{"key":"8_CR54","unstructured":"Perinatal HIV Guidelines Working Group: Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. October 12, 2006. http:\/\/aidsinfo.nih.gov . Accessed January 14, 2007."},{"key":"8_CR55","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(06)68887-9","volume":"367","author":"C. Daniel","year":"2006","unstructured":"Daniel C, Moh R, Minga A, et al.: CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006, 367:1981\u20131989.","journal-title":"Lancet"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-007-0008-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-007-0008-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-007-0008-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:15:40Z","timestamp":1559434540000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-007-0008-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,26]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s11904-007-0008-7","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,26]]}}}